Kyowa Kirin Co., Ltd. Overview
Pro stress-test →Kyowa Kirin is a Japanese specialty pharmaceutical company focused on developing innovative antibody-based therapeutics and gene therapies. The company targets unmet medical needs in oncology, nephrology, immunology, and rare diseases through its proprietary Potelligent platform and advanced drug discovery capabilities.
Strategic Profile
Pro stress-test →Positioned as a mid-sized global biopharmaceutical player with emphasis on biologics and specialty drugs rather than large-scale commodity pharmaceuticals. Strategic acquisitions like Orchard Therapeutics (2023) and the joint venture with Grünenthal demonstrate focus on expanding its rare disease and pain management portfolios while exiting lower-margin segments.
Competitive Landscape
Pro stress-test →Competes with larger integrated pharma companies (Eisai, Takeda) and specialist biotech firms in rare disease and oncology spaces. Differentiated by proprietary antibody platforms but lacks scale of global pharma majors. Regional competitors include other Japanese pharma players operating in similar therapeutic areas.
Industry Context
Kyowa Kirin Co., Ltd. operates in Specialty Pharmaceuticals & Biotechnology.
Key facts
Founded: 1949 · Headquarters: Tokyo, Japan · Employees: 5,670 · Revenue: $3.4B · Market cap: $8.5B